H.R. 4489: FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Before you vote › Federal bills
H.R. 4489: FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
111th Congress · introduced 2010-01-21 · Government Operations and Politics · Latest: Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
federal
Follow this bill, step by step
- Where it came from: introduced 2010-01-21 · official record
- Who proposed it: Rep. Lynch, Stephen F. [D-MA-9] · what a sponsor is
- What happened next: no floor votes in our records yet. Why?
- Where it stands now: Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote . Not final yet: this can still change. We check for updates every day.
- If it becomes law and spends money: follow the money to money laws, then agencies and contracts and grants.
Official title
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Plain summary
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act - Prohibits the Office of Personnel Management (OPM) from entering a contract or approving a health benefits plan with a carrier that is a party to a pharmacy benefit manager (PBM) carrier arrangement to provide or administer prescription drug coverage under the Federal Employees Health Benefits Program (FEHBP) unless the PBM and the carrier comply with requirements of this Act. Directs OPM to terminate a contract or discontinue a plan that fails to comply. Prohibits: (1) a pharmaceutical drug manufacturer or retail pharmacy from having a controlling interest in the PBM; or (2) the PBM from having a controlling interest in a retail pharmacy. Requires each carrier to certify PBM compliance annually. Prohibits OPM from permitting a carrier that has a controlling interest in a PBM to earn a profit from such interest with respect to an FEHBP contract. Sets forth requirements of PBM arrangements under the FEHBP, including regarding: (1) drug substitution restrictions; (2) PBM reimbursement of carriers; (3) sale by a PBM of utilization and claims data; (4) drug pricing and the basis for reimbursement; (5) provisions of an explanation of benefits to enrollees; (6) nondiscriminatory contracts regarding required participation; (7) OPM access to PBM contract information; (8) civil monetary penalties for making false statements or claims to the government; and (9) reports from drug manufacturers on average manufacturer prices for drugs each quarter.
Congressional Research Service summary (Introduced in House), quoted unchanged (nonpartisan). Read the source.
What a vote does
A “Yea” vote
If it passes both chambers and is signed, it becomes law.
A “Nay” vote
If it is not passed, current law stays as it is.
PSI Sci description of the legislative step (not an opinion).
What does this mean? (plain words)
Official text
FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
Source: Congressional Research Service summary (Introduced in House)
AI explanation – may be wrong, check the official text
No AI explanation yet. It takes up to a minute to write and is then saved for everyone.
Limited to a few requests an hour per person.
The strongest published arguments
Arguments for (supporters)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Arguments against (opponents)
Needs sources: no published arguments on this side yet. We only show items backed by a published source. Suggest one.
Alternatives
Needs sources: no published alternatives yet (for example a different bill, a law instead of an amendment, or keeping current law). We only show items backed by a published source. Suggest one.
How did my representative vote? · This bill's floor votes
Officials and money
Sponsor: Rep. Lynch, Stephen F. [D-MA-9] · 16 cosponsors
Cost estimate: No cost estimate published yet.
Cosponsors on this site
Lloyd Doggett (D-TX), Eleanor Holmes Norton (D-DC), Judy Chu (D-CA), Linda T. Sánchez (D-CA)
Sponsor's campaign money: Rep. Lynch, Stephen F. [D-MA-9] reported raising $1.1 million (2025–2026). Details. Shown for context only; it does not mean any donor supported this bill.
No linked floor roll calls in our collected records yet. This does not mean the bill has never had a vote. Check the official bill history.
Sources
- Congressional Research Service summary (Introduced in House)
- Congress.gov
- Data: GovInfo BILLSTATUS bulk data (Library of Congress), BILLSTATUS-111hr4489.xml <https://www.govinfo.gov/bulkdata/BILLSTATUS/111/hr>
Record fed-us-cong111-hr4489 · catalog fed-us-congress-bills-cong111 · updated 2026-11-15 by psicol fed-bills-cong111